ATYs306Q6fE

64
118. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L,
Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion:
results of the PAFAC trial. Eur Heart J. 2004;25:1385 –94.
119. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C,
Kottkamp H. Perception of atrial fibrillation before and after radiofrequency
cath-eter ablation: relevance of asymptomatic arrhythmia recurrence.
Circulation. 2005;112:307–13.
120. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio
F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL,
Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S,
Breithardt G. Early and comprehensive management of atrial fibrillation:
executive summary of the proceedings from the 2nd AFNET-EHRA consensus
conference ‘research perspectives in AF’. Eur Heart J. 2009;30:2969–77c.
121. Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial
fibrillation: A systematic review of age/gender differences and cardiovascular
out-comes. Int J Cardiol. 2015;191:172–7.
122. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence,
prognosis, quality of life, and management. J Interv Card Electrophysiol.
2000;4:369–82.
123. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation:
report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31:967–75.
124. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A,
Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic
stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated
patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36:281–7a.
125. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ,
Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey
KW, Fox KA, Califf RM, Piccini JP. Higher risk of death and stroke in pa-tients with
persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur
Heart J. 2015;36:288–96.
126. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan
S, Davies M, Lip GY, Allan TF. Screening versus routine practice in detection of
atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.
BMJ. 2007;335:383.
127. Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R,
Hepp T, Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R. Continuous
stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography
for detection of paroxysmal atrial fibrillation after stroke. Stroke.
2012;43: 2689–94.
128. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O’Donnell
M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB,
Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A,
Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani
M, EMBRACE Investigators and Coordinators. Atrial fibrillation in pa-tients with
cryptogenic stroke. N Engl J Med. 2014;370:2467–77.
129. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population
screening of 75- and 76-year-old men and women for silent atrial fibrillation
(STROKESTOP). Europace. 2013;15:135–40.
130. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK. Prevalence of
atrial fibrillation in the general population and in high-risk groups: the ECHOES
study. Europace. 2012;14:1553–9.
131. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies
M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic
screening (targeted and total population screening) versus routine practice for
the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
Health Technol Assess. 2005;9:iii–iv, ix–x, 1–74.
132. Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L,
Frykman-Kull V, Levin LA. Cost-effectiveness of mass screening for untreated atrial
fibrillation using intermittent ECG recording. Europace. 2015;17:1023–9.
133. Levin LA, Husberg M, Sobocinski PD, Kull VF, Friberg L, Rosenqvist M, Davidson T.
A cost-effectiveness analysis of screening for silent atrial fibrillation after
ischaemic stroke. Europace. 2015;17:207–14.
134. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown
atrial fibrillation. A systematic review. Thromb Haemost. 2013;110:213–22.
135. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial
fib-rillation in a 75-year-old population: implications for stroke prevention.
Circulation. 2013;127:930–7.
136. Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A,
Breithardt G, Kirchhof P. Prospective, multicentre validation of a simple, patientoperated
electrocardiographic system for the detection of arrhythmias and electrocardiographic
changes. Europace. 2009;11:1362–8.
137. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, Hofman C,
Houben RP. Validation and clinical use of a novel diagnostic device for screening
of atrial fibrillation. Europace. 2014;16:1291–5.
138. Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, Fought AJ, Topol
EJ. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch
electrocardiographic monitoring. Am J Med. 2014;127:95.e11–97.
139. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA,
Briffa T, Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW,
Freedman SB. Feasibility and cost-effectiveness of stroke prevention through
community screening for atrial fibrillation using iPhone ECG in pharmacies. The
SEARCH-AF study. Thromb Haemost. 2014;111:1167–76.
140. Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in the community.
Curr Opin Cardiol. 2014;29:28–35.
141. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain
E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser
SH, ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke.
N Engl J Med. 2012;366:120–9.
142. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger G,
Purerfellner H. Performance of a new leadless implantable cardiac monitor in
de-tecting and quantifying atrial fibrillation - results of the XPECT trial. Circ
Arrhythm Electrophysiol. 2010;3:141–7.
143. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van
Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M,
Deng WQ, Israel CW, Healey JS, ASSERT Investigators. Temporal relationship between
subclinical atrial fibrillation and embolic events. Circulation. 2014;129:
2094–9.
144. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M,
Lewalter T, Camm JA, Singer DE. Device-detected atrial fibrillation and risk for
stroke: an analysis of .10,000 patients from the SOS AF project (Stroke preventiOn
Strategies based on Atrial Fibrillation information from implanted devices).
Eur Heart J. 2014;35:508–16.
145. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L,
Catanzariti D, Molon G, Botto GL, La Rocca L, Grammatico A, Boriani G. Devicedetected
atrial tachyarrhythmias predict adverse outcome in real-world patients
with implantable biventricular defibrillators. J Am Coll Cardiol. 2011;57:167–72.
146. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD.
Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and
systemic emboli based on stored device data: a subgroup analysis of TRENDS.
Heart Rhythm. 2011;8:1416–23.
147. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi
D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from
implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm
Electrophysiol. 2009;2:474–80.
148. Lamas G. How much atrial fibrillation is too much atrial fibrillation? N Engl J
Med. 2012;366:178–80.
149. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K,
Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont
L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M,
Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson
NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger
L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F,
Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W,
Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Compre-hensive
risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic
options—a report from the 3rd Atrial Fibrillation Competence NET-work/European
Heart Rhythm Association consensus conference. Europace. 2012;14:8–27.
150. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider
K, Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S,
Dorian P, Vardas P, Breithardt G, Camm AJ. Comprehensive risk reduction in
patients with atrial fibrillation: Emerging diagnostic and thera-peutic options.
Executive summary of the report from the 3rd AFNET/EHRA consensus
conference. Thromb Haemost. 2011;106:1012–9.
1 51. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis
of atrial fibrillation after stroke and transient ischaemic attack: a systematic
review and meta-analysis. Lancet Neurol. 2015;14:377–87.
152. Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, Diener HC,
Di Lazzaro V, Rymer MM, Hogge L, Rogers TB, Ziegler PD, Assar MD. Predictors for
atrial fibrillation detection after cryptogenic stroke: Re-sults from CRYSTAL AF.
Neurology. 2016;86:261–9.
153. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III.
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter
clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke.
1993;24:35–41.
154. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Sacco RL,
Connolly SJ, Cryptogenic Stroke/ESUS International Working Group. Embolic
strokes of undetermined source: the case for a new clinical construct. Lancet
Neurol. 2014;13:429–38.
155. Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, Davies M, Lip
GY. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary
care practitioners and interpretative diagnostic software: analysis of data from
screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007;335:380.
156. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent
atrial fibrillation as documented by an implantable monitoring device:
im-plications for optimal patient care. J Am Coll Cardiol. 2004;43:47–52.
157. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass
Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation.
2015;131:2176–184.
158. Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: more than just one of a
kind. Eur Heart J. 2015;36:2356–63.
159. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, Hayes J, Eaker E,
Vidaillet H. Incidence and predictors of atrial flutter in the general population.
J Am Coll Cardiol. 2000;36:2242–6.
160. Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Munger TM, Shen WK, Hammill
SC, Friedman PA. The natural history of lone atrial flutter. Ann Intern Med.
2004;140:265–8.
161. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL,
Hammill SC, Shen WK, Gersh BJ. Long-term progression and outcomes with aging
in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation.
2007;115:3050–6.
162. Gillis AM, Rose MS. Temporal patterns of paroxysmal atrial fibrillation following
DDDR pacemaker implantation. Am J Cardiol. 2000;85:1445–50.